Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Staib

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
Frontiers in Pharmacology|April 2, 2021
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)Daniel Heudobler, Christian Schulz, Jürgen R Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2026
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo TrialSibylle Loibl, Michael Untch, Jens Huober, et al.
Blood|July 5, 2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaWalter Fiedler, Rolf Mesters, Heike Tinnefeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemiaThomas Büchner, Wolfgang E Berdel, Claudia Schoch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
Reviews in Clinical and Experimental Hematology|June 13, 2002
Acute myeloid leukemia: treatment over 60Thomas Büchner, Wolfgang Hiddemann, Wolfgang Berdel, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
Frontiers in Pharmacology|April 2, 2021
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)Daniel Heudobler, Christian Schulz, Jürgen R Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2026
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo TrialSibylle Loibl, Michael Untch, Jens Huober, et al.
Blood|July 5, 2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaWalter Fiedler, Rolf Mesters, Heike Tinnefeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemiaThomas Büchner, Wolfgang E Berdel, Claudia Schoch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
Reviews in Clinical and Experimental Hematology|June 13, 2002
Acute myeloid leukemia: treatment over 60Thomas Büchner, Wolfgang Hiddemann, Wolfgang Berdel, et al.
Pageof 9